← Eichor
Condition: Parp Inhibitor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Parp Inhibitor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or G
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT04511039An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability,
Phase 1/Phase 2 · 2 location(s) · Shanghai SciBrunch Therapeutics Co., Ltd. · NCT07359066Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxe
Phase 1/Phase 2 · 4 location(s) · Onconic Therapeutics Inc. · NCT05257993PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06074692Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Adva
Phase N/A · 16 location(s) · Hospices Civils de Lyon · NCT06572735Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping B
Phase 2 · 7 location(s) · Massachusetts General Hospital · NCT03990896Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tu
Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT05327010The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT07460180Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
Phase 4 · 1 location(s) · Wen-Ming Cao · NCT07695259Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06121557Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Phase 1 · 1 location(s) · Erasmus Medical Center · NCT05870423Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Phase 1 · 3 location(s) · Nerviano Medical Sciences · NCT06931626Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Phase 2 · 1 location(s) · Yonsei University · NCT07340164REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NA · 6 location(s) · Dana-Farber Cancer Institute · NCT06710548Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 8 location(s) · Impact Therapeutics, Inc. · NCT05269316Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06603506Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Ch
Phase 2 · 8 location(s) · Australasian Gastro-Intestinal Trials Group · NCT06441747Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Phase 1 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06976892CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Phase 1 · 1 location(s) · Lan Coffman · NCT05942300PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficie
Phase 2/Phase 3 · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07472140PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Phase 1 · 1 location(s) · Peter MacCallum Cancer Centre, Australia · NCT05053854Combination Therapy in Cancers With Mutations in DNA Repair Genes
Phase 1 · 1 location(s) · University of California, San Francisco · NCT05694715
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.